Cargando…
Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy
Cancer immunotherapy has already shown significant improvements by combining different antibodies specific for distinct immune checkpoints, such as Ipilimumab and Nivolumab. Here, we tested combinatorial treatments of immunomodulatory antibodies, previously generated in our laboratory, for their eff...
Autores principales: | Passariello, Margherita, Yoshioka, Asami, Takahashi, Kota, Hashimoto, Shu-ichi, Rapuano Lembo, Rosa, Manna, Lorenzo, Nakamura, Koji, De Lorenzo, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998846/ https://www.ncbi.nlm.nih.gov/pubmed/35408827 http://dx.doi.org/10.3390/ijms23073466 |
Ejemplares similares
-
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
por: Manna, Lorenzo, et al.
Publicado: (2023) -
Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo
por: Passariello, Margherita, et al.
Publicado: (2022) -
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022) -
Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
por: Passariello, Margherita, et al.
Publicado: (2023) -
Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
por: Vetrei, Cinzia, et al.
Publicado: (2021)